Cancer rarity and mortality: Evidence from a nationwide cohort study

Clicks: 21
ID: 326989
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #128 of 408 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Patients with rare cancers have consistently been reported to have poorer survival than patients with common cancers. We hypothesized that the excess mortality could be attributable to differences in tumor histology and stage at diagnosis and, explored whether it reflected a broader relationship between cancer incidence and mortality. METHODS: In a nationwide, population-based cohort study, we included adults diagnosed with a first primary solid malignant tumor in Denmark between 2004 and 2023. Cancers were classified according to Tier 2 of the RARECAREnet classification (rare cancer: incidence <6/100.000). Hazard ratios (HRs) of all-cause mortality according to rarity were estimated using Cox regression adjusted for age, sex and calendar period. Additional analyses further adjusted for tumor histology and stage at diagnosis. Tumor entities were also grouped into six incidence categories to examine survival across the incidence continuum. RESULTS: 20.6% of cancer patients were diagnosed with a rare cancer. Patients with rare cancers had a 74% higher mortality than those with common cancers (HR: 1.74, 95% CI: 1.72 to 1.76), but mortality did not generally increase with increasing rarity. After adjustment for tumor histology and stage at diagnosis, the HR was close to unity (HR: 0.96, 95% CI: 0.95 to 0.98). CONCLUSION: Patients with rare cancers experienced higher mortality than those with common cancers. The excess mortality was attenuated after adjustment for tumor histology and stage at diagnosis, indicating that these factors largely explain the survival disadvantage in rare cancers. Improving outcomes for patients with rare cancers should focus on earlier diagnosis and tumor-specific management.
Reference Key
openalex_W7204868581 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Simon Konig, Søren Friis, Trille Kristina Kjær, Jane Christensen, Mia Klinten Grand, Susanne Oksbjerg Dalton, Jan Wohlfahrt
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag308
URL
https://doi.org/10.1093/jnci/djag308
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.